Iron Drugs Market Analysis and Forecast 2024-2028: Rising Number of CKD Dialysis Centers in Emerging Economies is Driving Market Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The 
The iron drugs market is forecasted to grow by USD 4.58 billion during 2023-2028, accelerating at a CAGR of 10.87% during the forecast period.
The market is driven by growing prevalence of iron deficiency globally, growing awareness about importance of iron in maintaining overall health, and growing geriatric population.
The study identifies the growing number of CKD dialysis centers in emerging economies as one of the prime reasons driving the iron drugs market growth during the next few years. Also, growing recent developments related to iron drugs and increasing use of iron supplements in pregnancy will lead to sizable demand in the market.
The report provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.
The iron drugs market is segmented as below:
By Product
- Oral drugs
- IV drugs
By Age Group
- Adult
- Pediatric
By Region
- North America
- Europe
- Asia
- Rest of World (RoW)
A robust vendor analysis was designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading iron drugs market vendors.
Also, the iron drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Alinter Group Ltd.
- Alora Pharmaceuticals LLC
- Breckenridge Pharmaceutical Inc.
- Covis Pharma GmbH
- CSL Ltd.
- Daiichi Sankyo Co. Ltd.
- DSE Health Care Solutions Inc.
- GlaxoSmithKline plc
- Hiral Labs Ltd.
- McKesson Corp.
- NovaFerrum
- Pharmacosmos AS
- The Procter and Gamble Co.
- Reckitt Benckiser Group plc
- Rockwell Medical Inc.
- Sanofi SA
- Shield Therapeutics plc
- Zydus Lifesciences Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/msj9j7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
